Welcome to our dedicated page for ZSQR news (Ticker: ZSQR), a resource for investors and traders seeking the latest updates and insights on ZSQR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZSQR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZSQR's position in the market.
Z Squared (Nasdaq: ZSQR) announced completion of its business combination with Coeptis Therapeutics and a Nasdaq Global Market listing under ticker ZSQR, effective April 27, 2026 (CUSIP: 98878K108). The closing followed SEC effectiveness of the Form S-4 and Coeptis stockholder approval.
Following the transaction, the combined company has ~51.5 million shares outstanding; former Z Squared Opco stockholders own ~85% and existing public stockholders own ~15%. Coeptis effected a pro rata distribution of its pre-combination biopharmaceutical subsidiary ownership to its record-date stockholders.